Quarterly ResultAug 6, 2026, 07:08 AM
Cartesian Therapeutics Q2 Net Income $15.8M; Cash Runway into 2028
AI Summary
Cartesian Therapeutics reported a net income of $15.8 million for Q2 2026. The company extended its cash runway into 2028 with $149.3 million in cash, cash equivalents, and restricted cash, including $50 million from a new credit facility. Key pipeline updates include the Phase 3 AURORA trial data expected in 1Q27, a new strategic partnership with WestGene for an in vivo CAR-T platform, and progress in Phase 2 TRITON and Phase 1/2 HELIOS trials.
Key Highlights
- Net income for Q2 2026 was $15.8 million, compared to $15.9 million in Q2 2025.
- Cash, cash equivalents, and restricted cash totaled $149.3 million as of June 30, 2026.
- Cash runway extended into 2028, supported by up to $150 million non-dilutive financing.
- R&D expenses increased to $20.4 million in Q2 2026 from $14.9 million in Q2 2025.
- G&A expenses increased to $8.7 million in Q2 2026 from $7.2 million in Q2 2025.
- Phase 3 AURORA trial data for Descartes-08 in MG expected in 1Q27.
- New strategic partnership with WestGene for in vivo CAR-T platform; data expected 1H27.
- Phase 2 TRITON trial data in myositis expected in 1H27.
Price Impact
More from RNAC